曲妥珠单抗对HER2阳性乳腺癌患者术后辅助治疗的临床观察  被引量:10

Clinical observation on trastuzumab in postoperative adjuvant therapy of HER2-positive breast cancer

在线阅读下载全文

作  者:徐金明[1] 黎可[1] 陈轩[1] 童富云[1] 饶伟[1] 徐美玲[1] 

机构地区:[1]重庆市涪陵中心医院普通外科,408000

出  处:《重庆医学》2013年第9期1025-1026,共2页Chongqing medicine

摘  要:目的曲妥珠单抗对人类表皮生长因子受体2(HER2)阳性乳腺癌患者术后辅助治疗的效果和安全性。方法选择2006年5月至2011年12月在本院接受乳腺癌根治术患者136例,随机分为治疗组和对照组,治疗组68例,术后完成常规辅助化闻和(或)放疗后,每3个月随访观察。给予每3周1次的曲妥珠单抗辅助治疗,其中曲妥珠单抗首次以负荷剂量8mg/kg给药,然后每3周给予6mg/kg静脉滴注,21d为一个疗程。对照组68例,观察两组患者临床疗效。结果治疗组完全缓解、病情进展、5年生存期的患者百分比与对照组比较差异有统计学意义(P<0.05)。结论曲妥珠单抗是HER2阳性乳腺癌患者术后有效的治疗手段,可延长患者的生存期,不良反应轻,患者可以耐受。Objective To investigate the effect and safety of trastuzumab in postoperative adjuvant therapy of HER2-positive breast cancer.Methods 136 patients with breast cancer radical mastectomy in this hospital from May 2006 to December 2011 were selected and randomly divided into the treatment group(68 cases) and control group(68 cases).The treatment group was given trastuzumab once every 3 weeks as the adjuvant therapy.The initial loading dose was 8 mg/kg,and the subsequent dose was 6 mg/kg by intravenous drip once every 3 weeks,with 21 d as a treatment course.The efficacy and side effects were observed in the two groups.Results The complete remission(CR),progress disease(PD) and 5-year survival rate in the treatment group had statistical difference compared with the control group(P0.05).Conclusion Trastuzumab is effective in postoperative treatment of HER2-positive breast cancer,which extends the survival duration with mild adverse reactions.The patients are tolerable.

关 键 词:乳腺肿瘤 曲妥珠单抗 肿瘤辅助疗法 

分 类 号:R737.9[医药卫生—肿瘤]

 

参考文献:

正在载入数据...

 

二级参考文献:

正在载入数据...

 

耦合文献:

正在载入数据...

 

引证文献:

正在载入数据...

 

二级引证文献:

正在载入数据...

 

同被引文献:

正在载入数据...

 

相关期刊文献:

正在载入数据...

相关的主题
相关的作者对象
相关的机构对象